Appointment of Joint Corporate Broker

RNS Number : 9190N

MaxCyte, Inc.

03 February 2021

 

MaxCyte, Inc.

("MaxCyte" or the "Company") 

Appointment of Joint Corporate Broker

Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT, MXCL), a global cell-engineering and life sciences company, announces the appointment of Stifel Nicolaus Europe Limited as the Company's Joint Corporate Broker with immediate effect alongside existing Joint Corporate Brokers Panmure Gordon and Numis.

MaxCyte [phone] Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer Nominated Adviser and Joint Corporate Broker Panmure Gordon (UK) Limited Emma Earl / Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking) Joint Corporate Broker Numis Securities Ltd. James Black / Duncan Monteith / Matthew O'Dowd Joint Corporate Broker [phone] [phone] Stifel Nicolaus Europe Limited Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) Nick Adams (Corporate Broking) [phone] Financial PR Adviser Consilium Strategic Communications [phone] [e-mail] Mary-Jane Elliott / Chris Welsh

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

 

END

 

 

APPTJMFTMTBMBPB